Similarly, in the clinical study conducted by Truckenmueller et al., three of twenty patients with different grades of glioma (recurrent and heavily pre-treated), presented a tumour-to-liver ratio > 1 and qualified for 177Lu-PSMA RLT as a late-line therapy after recurrence. This evidence concerns the gene FOLH1 and neoplasm.